Kidney | Melanoma, Skin, Phase I

XTX301 in Patients With Advanced Solid Tumors

Volunteers
Health Professionals

What is the purpose of this trial?

This is a first-in-human, multicenter, Phase 1, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Chioma Amenechi

chioma.amenechi@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Thuy Tran, MD, PhD
Assistant Professor of Medicine (Medical Oncology)

Sub-Investigators

David Schoenfeld, MD, PhD
David A. Braun, MD, PhD
Harriet Kluger, MD
Jeffrey Ishizuka, MD, DPhil
Mario Sznol, MD
Michael Hurwitz, MD, PhD

Last Updated
02/23/2024
Study HIC
#2000035438